Clinical Trial Update: Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 trial comparing botulinum toxin A with anticholinergic therapy for neurogenic bladder in patients with multiple sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Neurogenic Bladder

Drugs mentioned

• Anticholinergic therapy (anticholinergic agent)
• Botulinum toxin A (botulinum toxin type A)

Snippet

Sponsor: Brigitte Schürch | Conditions: Urinary Bladder, Neurogenic, Multiple Sclerosis | Phase 4 | Status: TERMINATED